CorMedix Stock Price - CRMD

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 5.30 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
CorMedix Inc CRMD AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.09 1.73% 5.30 5.47 5.03 5.14 5.21 17:30:47
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,089 152,224 $ 5.28 $ 803,062 276,302 4.20 - 13.70
Last Trade Time Type Quantity Stock Price Currency
18:30:00 4,231 $ 5.30 USD

CorMedix Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 159.35M 30.07M $ -26.83M -1.50 - 25.72M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
3.91M $ - 0.00% 8.00 18.20%

more financials information »

CorMedix News

Loading Messages....

Latest CRMD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRMD Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week6.166.29584.865.2913479k-0.86-13.96%
1 Month8.258.644.866.3133322k-2.95-35.76%
3 Months99.934.867.5010262k-3.7-41.11%
6 Months9.119.994.867.7627351k-3.81-41.82%
1 Year1213.74.28.25792M-6.7-55.83%
3 Years12.913.70.86054.98181M-7.6-58.91%
5 Years7.85520.86058.10231M-2.55-32.48%

CorMedix Description

Cormedix Inc is a US-based biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. The Neutrolin product is designed to target unmet medical need.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.